• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Handelshøyskolen BI
  • Articles
  • Scientific articles
  • View Item
  •   Home
  • Handelshøyskolen BI
  • Articles
  • Scientific articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Should pharmaceutical costs be curbed?

Brekke, Kurt R.; Dalen, Dag Morten; Strøm, Steinar
Journal article, Peer reviewed
Thumbnail
View/Open
Dalen_NEPR_2012.pdf (439.6Kb)
URI
http://hdl.handle.net/11250/93886
Date
2012
Metadata
Show full item record
Collections
  • Scientific articles [1334]
Original version
http://dx.doi.org/10.6027/TN2013-514
Abstract
Pharmaceuticals account for almost a fifth of total health spending in

OECD-countries. Both pharmaceutical innovations and the aging of the

population explain the increasing importance of pharmaceuticals in health

care. Due to the importance of patent protection and insurance coverage,

pharmaceutical markets are subjected to economic regulation – both on

the supply-side and the demand-side. In this paper, we briefly review the

Nordic pharmaceutical market, before explaining the main regulatory

policy measures taken by governments in these countries. Empirical research

has been undertaken to investigate regulation and competition, and

we provide a review of some of the findings.
Description
This is an Open Access journal. www.norden.org
Publisher
Nordisk ministerråd
Journal
Nordic Economic Policy Review

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit